Selinexor

Report
32 Pages
October 2018
Region: Global
Citeline
ID: 4775277

Drug Overview
Selinexor (Karyopharm Therapeutics/Ono Pharmaceutical) selectively inhibits the transport protein exportin-1 (XPO1), also called chromosome region maintenance-1.

XPO1 is responsible for the transport of around 220 proteins from the nucleus of the cell to the cytoplasm, including many growth regulators and tumor suppressors. By preventing the export of these proteins, they are retained in the nucleus, leading to growth inhibition. XPO1 has been shown to be crucial for multiple myeloma (MM) cell survival, and selinexor inhibits MM cell growth and induces apoptosis in vivo and in vitro. It has also been shown to overcome proteasome inhibitor resistance in cells when added to Kyprolis (carfilzomib; Amgen/Ono Pharmaceutical) or Velcade (bortezomib; Takeda/Johnson & Johnson).

OVERVIEW

Drug Overview
Product Profiles
selinexor : NHL: Diffuse large B-cell lymphoma (DLBCL)
selinexor : Multiple myeloma

LIST OF FIGURES

Figure 1: Selinexor for diffuse large B-cell lymphoma – SWOT analysis
Figure 2: The authors drug assessment summary for selinexor in diffuse large B-cell lymphoma
Figure 3: The authors drug assessment summary for selinexor in diffuse large B-cell lymphoma
Figure 4: Selinexor sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Selinexor for multiple myeloma – SWOT analysis
Figure 6: The authors drug assessment summary for selinexor in multiple myeloma
Figure 7: The authors drug assessment summary for selinexor in multiple myeloma
Figure 8: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES

Table 1: Selinexor drug profile
Table 2: Selinexor pivotal trial data in diffuse large B-cell lymphoma
Table 3: Selinexor sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 4: Selinexor drug profile
Table 5: Selinexor Phase III trial in multiple myeloma
Table 6: Selinexor early-phase data in multiple myeloma
Table 7: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 8: Patients treated with selinexor across the US, Japan, and five major EU markets, by country, 2017–26

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9615EUR$10,000USD£8,249GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47116EUR$49,000USD£40,419GBP

Table of Contents

Related Topics

Related Reports

Soft Tissue Sarcoma - Pipeline Insight, 2024

Global Hematologic Malignancies Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

CAR T - Pipeline Insight, 2024

CAR-T Therapy in Haematological Malignancy: Update Bulletin #2

Global CAR T-Cell Therapy Market 2030 by Drug type, Indication, Target Antigen, End-user and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints